期刊
BIOMARKERS IN MEDICINE
卷 11, 期 12, 页码 1149-1159出版社
FUTURE MEDICINE LTD
DOI: 10.2217/bmm-2017-0138
关键词
biomarkers; bladder cancer; clinical trials; CTLA-4; ICOS; immune checkpoints; kidney cancer; neoadjuvant; PD-1; PD-L1; prostate cancer; vaccines; VISTA
Immune biomarkers encompass a wide range of blood-borne and cell-associated molecules whose detection or expression may change in response to an immune therapy. These immune therapies encompass a range of platforms including autologous cellular products, in other words, dendritic cells, prime boost DNA vaccines, chimeric antigen receptor (CAR) T cells and checkpoint inhibitors. The response to checkpoint inhibitors by a particular cancer may not be necessarily associated with a change in a particular immune biomarker; other immune biomarkers are needed to assess their association with treatment response or a change in the biology that can impact on the immunologic milieu. How these potential biomarkers can be incorporated into clinical trial design, and their role in interrogating the immunologic milieu will be discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据